SUMMARY: Background: Docetaxel and paclitaxel are among the most active substances for the treatment of breast cancer. As both drugs are used today in adjuvant regimens, efficacy data from pivotal trials in the metastatic setting in taxane-naive populations cannot reliably be used as references. Patients and Methods: The Taxane Re-Challenge Cohort Study identified participants from 6 prospective (neo-)adjuvant taxane-based studies with recurrent disease and collected data on their subsequent treatment. Out of 381 recurrent patients, 106 (27.8%) were re-challenged with a taxane-based treatment as first- or later-line therapy for recurrent disease. Results: Taxanes were used as first-line therapy in 74 patients and showed a response rate of 48.6% (including complete responses in 27.0%). The response rate was dependent on the disease-free interval (<1 year: 34.8%; 1-2 years: 42.9%; >2 years: 63.3%; p = 0.04) and visceral metastasis (present: 62.5%; not present 32.4%; p = 0.01). Patients without visceral metastasis and with a disease-free interval of >2 years achieved the longest overall survival. Hormone and HER2 receptor status were not predictive; however, triple-negative tumors responded in 50.0%. The overall response rate of later-line taxane-based treatment was 28.2%. Conclusion: Re-challenging taxanes appears to be effective and therefore represents a reasonable option in this population.
SUMMARY: Background: Docetaxel and paclitaxel are among the most active substances for the treatment of breast cancer. As both drugs are used today in adjuvant regimens, efficacy data from pivotal trials in the metastatic setting in taxane-naive populations cannot reliably be used as references. Patients and Methods: The Taxane Re-Challenge Cohort Study identified participants from 6 prospective (neo-)adjuvant taxane-based studies with recurrent disease and collected data on their subsequent treatment. Out of 381 recurrent patients, 106 (27.8%) were re-challenged with a taxane-based treatment as first- or later-line therapy for recurrent disease. Results:Taxanes were used as first-line therapy in 74 patients and showed a response rate of 48.6% (including complete responses in 27.0%). The response rate was dependent on the disease-free interval (<1 year: 34.8%; 1-2 years: 42.9%; >2 years: 63.3%; p = 0.04) and visceral metastasis (present: 62.5%; not present 32.4%; p = 0.01). Patients without visceral metastasis and with a disease-free interval of >2 years achieved the longest overall survival. Hormone and HER2 receptor status were not predictive; however, triple-negative tumors responded in 50.0%. The overall response rate of later-line taxane-based treatment was 28.2%. Conclusion: Re-challenging taxanes appears to be effective and therefore represents a reasonable option in this population.
Authors: J M Nabholtz; K Gelmon; M Bontenbal; M Spielmann; G Catimel; P Conte; U Klaassen; M Namer; J Bonneterre; P Fumoleau; B Winograd Journal: J Clin Oncol Date: 1996-06 Impact factor: 44.544
Authors: G von Minckwitz; J-U Blohmer; G Raab; A Löhr; B Gerber; G Heinrich; H Eidtmann; M Kaufmann; J Hilfrich; C Jackisch; I Zuna; S D Costa Journal: Ann Oncol Date: 2005-01 Impact factor: 32.976
Authors: C Jackisch; M Untch; D Chatsiproios; C Lamparter; F Overkamp; W Lichtenegger; W Rönsberg; C Thomssen; G von Minckwitz Journal: Zentralbl Gynakol Date: 2006-12
Authors: S Chan; K Friedrichs; D Noel; T Pintér; S Van Belle; D Vorobiof; R Duarte; M Gil Gil; I Bodrogi; E Murray; L Yelle; G von Minckwitz; S Korec; P Simmonds; F Buzzi; R González Mancha; G Richardson; E Walpole; M Ronzoni; M Murawsky; M Alakl; A Riva; J Crown Journal: J Clin Oncol Date: 1999-08 Impact factor: 44.544
Authors: Michel Marty; Francesco Cognetti; Dominique Maraninchi; Ray Snyder; Louis Mauriac; Michèle Tubiana-Hulin; Stephen Chan; David Grimes; Antonio Antón; Ana Lluch; John Kennedy; Kenneth O'Byrne; PierFranco Conte; Michael Green; Carol Ward; Karen Mayne; Jean-Marc Extra Journal: J Clin Oncol Date: 2005-05-23 Impact factor: 44.544
Authors: Jens Huober; Gunter von Minckwitz; Carsten Denkert; Hans Tesch; Erich Weiss; Dirk Michael Zahm; Antje Belau; Fariba Khandan; Maik Hauschild; Christoph Thomssen; Bernhard Högel; Silvia Darb-Esfahani; Keyur Mehta; Sibylle Loibl Journal: Breast Cancer Res Treat Date: 2010-08-10 Impact factor: 4.872
Authors: Cornelia Liedtke; Chafika Mazouni; Kenneth R Hess; Fabrice André; Attila Tordai; Jaime A Mejia; W Fraser Symmans; Ana M Gonzalez-Angulo; Bryan Hennessy; Marjorie Green; Massimo Cristofanilli; Gabriel N Hortobagyi; Lajos Pusztai Journal: J Clin Oncol Date: 2008-02-04 Impact factor: 44.544